ArticleFrontiers in public health2018
Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs-a Systematic Literature Review. Next Steps in Methodology Development?
Article in Frontiers in public health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review.PharmacoEconomics · 2024Pooled it
- A multicriteria decision analysis (MCDA) tool to purchase implantable medical devices in Egypt.BMC medical informatics and decision making · 2022Pooled it
- Criteria and Scoring Functions Used in Multi-criteria Decision Analysis and Value Frameworks for the Assessment of Rare Disease Therapies: A Systematic Literature Review.PharmacoEconomics - open · 2021Pooled it
- A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries.Frontiers in public health · 2019Pooled it
- Comparative clinical evaluation of endothelin receptor antagonists in pulmonary arterial hypertension using a multi-criteria decision analysis framework.International journal of clinical pharmacy · 2026Article
- Strategic health policy priorities for health technology assessment development in Iran.Journal of preventive medicine and hygiene · 2026Article
- Characterizing multi-criteria decision analysis, risk stratification, and hotspot analysis methods to optimise health policymaking and evidence translation for medicines in low- and middle-income countries: A scoping review.Gates open research · 2026Article
- Setting priorities for healthcare interventions in Indonesia: a comprehensive conceptual framework.International journal for equity in health · 2025Review
- Multi-criteria decision analysis of value evaluation of rare disease medical insurance drugs in China.BMC public health · 2025Article
- Driving the future of value-based healthcare in the Gulf Cooperation Council: a roadmap for achieving sustainable access to specialty pharmaceuticals.Frontiers in public health · 2025Article
- Establishment of a value assessment framework for orphan medicinal products in China.Orphanet journal of rare diseases · 2024Article
- The need for a broad perspective when assessing value-for-money for out-of-hours primary care.Primary health care research & development · 2024Review
- Development of an multicriteria decision analysis framework for rare disease reimbursement prioritization in Malaysia.International journal of technology assessment in health care · 2024Article
- Article
- A multiple criteria decision analysis to establish the use cases and candidate point of care tests to enter into a platform trial of multipleNIHR open research · 2024Article
- A comparative evaluation of child health care in China using multicriteria decision analysis methods.BMC health services research · 2023Article
- Innovative thinking of clinical investigation for rare disease drug development.Orphanet journal of rare diseases · 2023Review
- Using multi-criteria decision analysis to describe stakeholder preferences for new quality improvement initiatives that could optimise prescribing in England.Frontiers in health services · 2023Article
- A Cross-Sectional Study of Price and Affordability of Drugs for Rare Diseases in Shandong Province, China.International journal of environmental research and public health · 2022Article
- Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States.Journal of managed care & specialty pharmacy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.